ALFA Finder| Revenue growth | 18.9% YoY for FY26; 50% YoY for Q4. |
|---|---|
| Margins | EBITDA margin at 35.5%, surpassing guided range of 33-35%. |
| Order book | 300 metric ton capacity locked with large users for CVS product. |
| Demand visibility | Strong demand in Europe (40% share) and LATAM. |
| Management confidence | High; iterating guidance and trajectory toward ₹1,000cr milestone. |
Growth
FY26 revenue grew 18.9% YoY to ₹828cr; EBITDA at ₹294cr (35.5% margin); PAT at ₹209cr.
Outlook
Targeting ₹1,000cr revenue by FY27; ₹200cr capex for Patalganga Phase 1; scheduled August maintenance shutdown.
Risks
Industry headwinds from geopolitical issues, supply chain disruptions, and elevated crude/solvent prices impacting revenue.
Earnings Call filed with NSE, NSE: SUPRIYA. Summary written with AI assistance from the document.
Supriya Lifescience Limited: key numbers
- Share price
- ₹637.90
- Market cap
- ₹5,134 Cr
- Revenue (annual)
- ₹827.9 Cr
- Net profit (annual)
- ₹209.1 Cr
- P/E (TTM)
- 29.0×Sector 43.8×
- Promoter holding
- 68.30%+0.00% QoQ
- FII holding
- 6.45%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Supriya Lifescience Limited
All →Supriya Lifescience Results Update
Supriya Lifescience's Q2 FY27 revenue rose 3.2%, but EBITDA and PAT fell sharply. Ambernath ramp-up costs and LATAM regulatory shifts hurt margins.
Supriya Lifescience Q2 FY27 Results: Net Profit ₹29.2 Cr, Down 42.1% YoY
Supriya Lifescience Ltd reported revenue from operations of ₹206.3 Cr (+3.3% YoY) and net profit of ₹29.2 Cr (-42.1% YoY) for Q2 FY27.
- Key figure
- Net profit ₹29.2 Cr · -42.1% YoY
Supriya Lifescience Legal & Regulatory
Supriya Lifescience disclosed that its General Manager, Sales & Marketing, was granted bail in an NDPS Act case. The company says the order has no material impact.
Supriya Lifescience Board Meeting Date
Supriya Lifescience will hold a board meeting on 6 November 2026 to consider unaudited results for the quarter and half year ended 30 September 2026. The trading window stays closed until 48 hours after results are declared.
Supriya Lifescience Legal & Regulatory
Supriya Lifescience disclosed a pending case was admitted by the Supreme Court. An interim order precludes coercive action against directors while the matter is sub judice.
Supriya Lifescience Other Announcement
Supriya Lifescience disclosed a CRISIL ESG rating of 65 in the Strong category. No financial or operational event accompanies the disclosure.